In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

Brightstar Resources has recorded a best hit of 20.39m at 3.03g/t gold in final assays from last year’s diamond drilling ...

Aurumin Ltd and potential JV partner Newcam have kicked-off drilling for iron ore at the Central Sandstone project in WA, ...